Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial-Reference-Cited by-同舟云学术

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial

Published:2022-08-31 Issue:4 Volume:3 Page:1241-1251
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Spencer Andrew¹,Samoilova Olga²,Chng Wee‐Joo³,Labotka Richard⁴,Li Cong⁴,Wu Kwang‐Wei⁵,Saxena Nakul⁵,Yan Xu⁶,Lee Jae Hoon⁷,Beksac Meral⁸^ORCID

Affiliation:

1. The Alfred Hospital‐Monash University Melbourne Victoria Australia

2. State Budget Institution of Healthcare of Nizhny Novgorod Region Nizhny Novgorod Regional Clinical Hospital Nizhny Novgorod Russia

3. National University Hospital Singapore Singapore

4. Takeda Development Center Americas Lexington Massachusetts USA

5. Takeda Pharmaceuticals International AG Singapore Singapore

6. State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood Diseases Haihe Laboratory of Cell Ecosystem Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Tianjin China

7. Gachon University Gil Medical Center Namdong‐gu South Korea

8. Department of Hematology Ankara University School of Medicine Dikimevi Turkey

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.548

Reference24 articles.

1. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

2. The Global Cancer Observatory.Globocan multiple myeloma factsheet. World Health Organization; Lyon France: International Agency for Research on Cancer;2020.https://gco.iarc.fr/today/data/factsheets/cancers/35‐Multiple‐myeloma‐fact‐sheet.pdf

3. The Global Cancer Observatory.Globocan: multiple myeloma. World Health Organization; Lyon France: International Agency for Research on Cancer;2020.https://gco.iarc.fr/today/online‐analysis‐map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=35&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&projection=natural‐earth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&show_ranking=0&rotate=%255B10%252C0%255D

4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

5. US Food and Drug Administration.DARZALEX®: highlights of prescribing information. Accessed 6 Feb 2022. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Detection of Precursor Diseases of Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-08

2. Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey;Journal of Chemotherapy;2023-05-21